Heidelberg Pharma AG provided financial guidance for 2021. The Executive Management Board expects the Heidelberg Pharma Group to generate between EUR 5.5 million and EUR 7.5 million in sales revenue and other income (2020: EUR 9.6 million) for the 2021 fiscal year. Earnings before interest and taxes (EBIT) for 2021 are expected to be between EUR -30.0 million and EUR -34.0 million (2020: EUR -18.3 million).